Cost-effectiveness modelling of anti-VEGF treatments has been more common in other retinal diseases such as diabetic retinopathy (DR), with simulation-based studies showing mixed results depending on setting and perspective. This evidence concerns the gene VEGFA and diabetic retinopathy.